Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue

Novo Nordisk announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enroll about 155 people, are expected to be reported in 2011.
GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. It stimulates the release of insulin only when blood sugar levels become too high. In people with type 2 diabetes, GLP-1 secretion is often impaired.

ASweetLife Team

FDA Approves First GLP-1 Pill, Novo Nordisk’s Rybelsus TheU.S. FDA has approved Rybelsus (semaglutide), the first and only glucagon-like peptide-1 (GLP-1) analog in a pill. “GLP-1 receptor agonists are effective medications for people with type 2 diabetes but have…
Why Do Long and Short Acting Insulin Pens Look… On the top Tresiba long-acting basal insulin, in the middle old Fiasp and on the bottom new Fiasp ultra-rapid insulin Please Novo Nordisk, what are you thinking? Both your Tresiba…
FDA Rejects Sanofi-Lexicon Oral Medication for Type… The FDA has denied approval of Sanofi and Lexicon's drug, sotagliflozin, as an add-on to insulin therapy in the treatment of Type 1 diabetes. This decision comes just a few…
iLet Bihormonal Bionic Pancreas Clinical Trial Begins Are two hormones better than one? A new clinical trial aims to find out. Massachusetts startup Beta Bionics and Danish biotech firm Zealand Pharma have announced the beginning of a…
Fiasp Faster-Acting Insulin Approved for Children… Two years after the approval of Fiasp faster-acting insulin in adults, Novo Nordisk has announced the FDA approval of Fiasp for use as a new mealtime insulin option for children…